Overview of α-blocker therapy for benign prostatic hyperplasia

被引：37

作者：

Narayan, P ^{[1
]}

Tewari, A ^{[1
]}

机构：

[1] Univ Florida, Coll Med, Div Urol, VAMC, Gainesville, FL 32610 USA

来源：

UROLOGY | 1998年 / 51卷 / 4A期

关键词：

D O I：

10.1016/S0090-4295(98)00054-5

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Management of benign prostatic hyperplasia (BPH) is rapidly changing. Established surgical procedures are being replaced by minimally invasive modalities such as electrovaporization and transurethral needle ablation. Improved understanding of pathophysiology and developments in molecular biology has provided drugs for alleviating the symptoms of prostatic enlargement. Currently, medical therapy is the first-line treatment modality in the management of BPH. There are two types of medical treatment available: alpha-adrenoceptor-blockers and 5-alpha-reductase inhibitors. Alpha-blockers relieve the dynamic component of obstruction whereas 5-alpha-reductase inhibitors relieve the mechanical component of obstruction. At present, alpha-blockers are used most frequently. However, they do have significant cardiovascular side effects. More uroselective alpha-blockers have recently become available and may reduce the risk of cardiovascular side effects. This review summarizes relevant literature on the use of alpha-blockers in the treatment of BPH. (C) 1998, Elsevier Science Inc. All rights reserved.

引用

页码：38 / 45

页数：8

共 58 条

[1]

Abrams P, 1997, NEUROUROL URODYNAM, V16, P79

[2] TAMSULOSIN, A SELECTIVE ALPHA(1C)-ADRENOCEPTOR ANTAGONIST - A RANDOMIZED, CONTROLLED TRIAL IN PATIENTS WITH BENIGN PROSTATIC OBSTRUCTION (SYMPTOMATIC BPH) [J].

ABRAMS, P ;

SCHULMAN, CC ;

VAAGE, S ;

ABEL, P ;

BAXBY, K ;

BOEMINGHAUS, F ;

DELAERE, KPJ ;

DENIS, L ;

DIJKMAN, GA ;

HASSELLUND, S ;

HOHENFELLNER, R ;

JANKNEGT, RA ;

KAPPER, BJ ;

KARTHAUS, HFM ;

KHOE, GSS ;

KIL, PJM ;

KROMANNANDERSEN, B ;

LELIEFELD, HHJ ;

LOCK, TMTW ;

MOHR, M ;

MOMMSEN, S ;

OGREID, P ;

OTTO, RW ;

PLASMAN, JWMH ;

PULL, HC ;

RYTTOV, N ;

TOLLEY, DA ;

VENEMA, PL ;

WYNDAELE, JJ ;

YPMA, AFGVM .

BRITISH JOURNAL OF UROLOGY, 1995, 76 (03) :325-336

[3]

APPELL RA, 1994, SEMIN NEPHROL, V14, P531

[4] Management of benign prostatic hyperplasia [J].

Barry, M ;

Roehrborn, C .

ANNUAL REVIEW OF MEDICINE, 1997, 48 :177-189

[5] A nationwide survey of practicing urologists: Current management of benign prostatic hyperplasia and clinically localized prostate cancer [J].

Barry, MJ ;

Fowler, FJ ;

Bin, L ;

Oesterling, JE .

JOURNAL OF UROLOGY, 1997, 158 (02) :488-491

[6]

BRUSKEWITZ RC, 1992, GERIATRICS, V47, P39

[7] ALPHA-BLOCKING TREATMENT WITH ALFUZOSIN IN SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA - COMPARATIVE-STUDY WITH PRAZOSIN [J].

BUZELIN, JM ;

HEBERT, M ;

BLONDIN, P .

BRITISH JOURNAL OF UROLOGY, 1993, 72 (06) :922-927

[8] Clinical uroselectivity: Evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction [J].

Buzelin, JM ;

DelaucheCavallier, MC ;

Roth, S ;

GeffriaudRicouard, C ;

Santoni, JP .

BRITISH JOURNAL OF UROLOGY, 1997, 79 (06) :898-904

[9]

Bylund D B, 1995, Ann N Y Acad Sci, V763, P1, DOI 10.1111/j.1749-6632.1995.tb32386.x

[10] VASCULAR ALPHA-ADRENOCEPTORS - FROM THE GENE TO THE HUMAN [J].

BYLUND, DB ;

REGAN, JW ;

FABER, JE ;

HIEBLE, JP ;

TRIGGLE, CR ;

RUFFOLO, RR .

CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (05) :533-543

← 1 2 3 4 5 6 →